Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $121 | $241 | $123 | $139 |
| Short-Term Investments | $30 | $0 | $0 | $0 |
| Receivables | $4 | $6 | $3 | $2 |
| Inventory | $2 | $0 | -$9 | -$6 |
| Other Curr. Assets | $9 | $5 | $6 | $5 |
| Total Curr. Assets | $165 | $241 | $123 | $140 |
| Property Plant & Equip (Net) | $5 | $4 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $15 | $11 | $7 |
| Total NC Assets | $6 | $19 | $14 | $10 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $171 | $260 | $137 | $150 |
| Liabilities | – | – | – | – |
| Payables | $4 | $4 | $3 | $2 |
| Short-Term Debt | $15 | $2 | $1 | $1 |
| Tax Payable | $0 | $2 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $16 | $0 |
| Other Curr. Liab. | $22 | $16 | $37 | $8 |
| Total Curr. Liab. | $41 | $55 | $41 | $11 |
| LT Debt | $96 | $72 | $43 | $3 |
| Deferred Rev, NC | $18 | $16 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $30 | $0 | $0 |
| Total NC Liab. | $114 | $89 | $43 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $2 | $3 | $3 |
| Total Liabilities | $154 | $144 | $83 | $13 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $4 | $4 | $4 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$572 | -$431 | -$411 | -$312 |
| AOCI | -$0 | $0 | $0 | -$0 |
| Other Equity | $589 | $542 | $460 | $445 |
| Total Equity | $17 | $116 | $53 | $137 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $171 | $260 | $137 | $150 |
| Net Debt | -$10 | -$167 | -$80 | -$135 |